Titlebook: Contemporary Bone Marrow Transplantation; Mammen Chandy,Vivek S. Radhakrishnan,Reghu K. Suku Reference work 2021 Springer Nature Switzerla

Wilder

書目名稱Contemporary Bone Marrow Transplantation影響因子(影響力)




書目名稱Contemporary Bone Marrow Transplantation影響因子(影響力)學(xué)科排名




書目名稱Contemporary Bone Marrow Transplantation網(wǎng)絡(luò)公開度




書目名稱Contemporary Bone Marrow Transplantation網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Contemporary Bone Marrow Transplantation被引頻次




書目名稱Contemporary Bone Marrow Transplantation被引頻次學(xué)科排名




書目名稱Contemporary Bone Marrow Transplantation年度引用




書目名稱Contemporary Bone Marrow Transplantation年度引用學(xué)科排名




書目名稱Contemporary Bone Marrow Transplantation讀者反饋




書目名稱Contemporary Bone Marrow Transplantation讀者反饋學(xué)科排名

祝賀

OATH

不公開

嚴(yán)厲批評(píng)

Chimerism in Hematopoietic Stem Cell Transplantationes in the successful engraftment of the donor stem cells in the host environment. The degree of donor cell component in the recovering hematopoiesis in the host is a critical factor which affects posttransplant immunomodulation, relapse of primary disease, posttransplant complications, and ultimatel

EXTOL

HSCT in Malignanciesers or solid organ cancer. The better understanding of disease physiopathology and the continuous development of new therapeutic strategies has an incessant impact in HCT indication. In addition, the refinement in HCT techniques and supportive care has remarkable reduced transplant-related mortality

EXTOL

micronutrients

Hemopoietic Stem Cell Transplant for Non-hematological Disordersrders is perhaps less obvious since the blood cells themselves function normally and there is no malignancy. The application of HCT in non-hematological disease is a growing area and is likely to concern all transplant physicians in the coming decades..HCT in leukemia is intuitive, even to the lay p

紡織品

Allogeneic Transplant Overview and Matched Related Donor Transplantignancies and other malignant and nonmalignant diseases. Since the first allogeneic transplants more than five decades ago, significant advances have occurred in transplantation technology, donor availability, and supportive care that have made transplantation safer and increasingly available to pat

陳舊

Haploidentical Transplantation: Challenges and Solutions hematological malignancies. The primary reason for this has been the emergence of posttransplantation cyclophosphamide as graft-versus-host disease (GVHD) prophylaxis, which by dint of both, its ease of application and impressive outcomes, has made HFD-HCT feasible across the globe. Studies have co